Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Naurex Rapid Antidepressant Enhances Plasticity | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Naurex Rapid Antidepressant Enhances Plasticity

Preclinical data supports mechanism of action

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Naurex Inc. has presented preclinical data demonstrating that GLYX-13, its rapid-acting novel antidepressant, enhances synaptic plasticity, its hypothesized mechanism of action. The data were presented at the 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, FL.

In these studies, GLYX-13 also enhanced enrichment of specific genes associated with synaptic plasticity and long-term depression. GLYX-13 is currently in a Phase IIb repeat-dose trial in patients with depression who experience an inadequate response to their current antidepressants. In an earlier Phase II trial, a single dose of GLYX-13 produced statistically significant and long-lasting reductions in depression scores within 24 hours in patients with major depressive disorder who had failed treatment with one or more antidepressant agents. Data from the Phase IIb trial are expected early in 2014.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics